AstraZeneca Plc (NASDAQ: AZN) announced on Friday that its Phase 3 SERENA-4 trial, evaluating the oral selective estrogen receptor degrader (SERD) Etcamah (camizestrant) in combination with palbociclib as a first-line treatment for ER-positive, HER2-negative advanced breast cancer, failed to meet its primary endpoint. While a numerical improvement in progression-free survival (PFS) was observed, it did not reach statistical significance.

Bloomberg Intelligence analyst John Murphy commented that this setback could reduce the drug's projected 2035 sales by between $2.6 billion and $3.8 billion. RBC Capital Markets analyst Trung Huynh had previously estimated the potential revenue for the breast cancer drug at around $1 billion.

Despite the disappointment, market expectations for success in this specific indication were already low, especially after a competing experimental drug from Roche Holding, giredestrant, failed to demonstrate a benefit in a similar setting. For Etcamah, a more significant test will come from several ongoing studies targeting a substantially larger patient population, and some analysts had not factored in sales from this indication into their forecasts.

Traditional SERDs like fulvestrant require intramuscular injection, which results in poor patient compliance. Oral SERDs, taken once daily, theoretically have the potential to replace aromatase inhibitors (AIs) as the standard first-line endocrine therapy, representing a significant market opportunity. However, in reality, oral SERDs combined with CDK4/6 inhibitors have consistently failed to outperform AIs plus CDK4/6 inhibitors in the overall first-line patient population. Neither AstraZeneca's Etcamah nor Roche's giredestrant has been able to achieve this.

The challenge may lie in the fact that AIs are already highly effective, with PFS exceeding 28 months in the ER-positive, HER2-negative first-line population. Significantly extending this further with an oral SERD proves difficult. Alternatively, the ER degradation efficiency of oral SERDs may be insufficient to demonstrate a differentiated advantage across the general population.

However, oral SERDs still hold promise, particularly in the patient subgroup with ESR1 mutations. ESR1 mutations are a key mechanism of resistance to endocrine therapy in ER-positive breast cancer. Approximately 30-40% of patients develop ESR1 mutations during AI treatment, where the mutated ER remains persistently active in low-estrogen environments, driving tumor growth.

Etcamah's SERENA-6 trial specifically targeted this patient population. In the study, 315 patients were monitored via ctDNA testing for ESR1 mutations every 2-3 months. Upon detection, patients were randomized to either switch to Etcamah plus a CDK4/6 inhibitor or continue an AI plus a CDK4/6 inhibitor. The results were compelling: PFS was 16.0 months versus 9.2 months, with a hazard ratio of 0.44, indicating a 56% reduction in the risk of disease progression or death. PFS2 was also significantly improved (25.7 vs 19.1 months, HR 0.63, p=0.00373).

Based on this data, the FDA granted accelerated approval on September 8 for Etcamah in combination with a CDK4/6 inhibitor for HR-positive, HER2-negative locally advanced or metastatic breast cancer with ESR1 mutations emerging during AI plus CDK4/6 therapy. Approvals have also been granted in the EU, Japan, and several other countries.

Following the SERENA-4 setback, Susan Galbraith, Executive Vice President of Oncology Haematology R&D at AstraZeneca, stated clearly: "While we are disappointed with the SERENA-4 outcome, it further clarifies our focus on maximizing patient benefit based on SERENA-6 and reinforces the importance of ESR1 mutation testing in the first-line treatment setting."

The SERENA-4 failure does not signal the end of the story for Etcamah. AstraZeneca's primary strategic bet lies in the adjuvant treatment of early-stage breast cancer. Two Phase 3 trials, CAMBRIA-1 and CAMBRIA-2, are planned to enroll approximately 10,000 patients with intermediate-high recurrence risk. These studies will evaluate Etcamah as monotherapy, in combination with a CDK4/6 inhibitor, and after CDK4/6 inhibitor treatment. CAMBRIA-1 will compare 5 years of extended adjuvant Etcamah against standard endocrine therapy in intermediate-high risk patients, while CAMBRIA-2 will compare 7 years of upfront adjuvant Etcamah versus standard endocrine therapy in intermediate-high/high risk patients. Collectively, this represents the largest development program for an oral SERD in early-stage breast cancer.

Their rationale is that while oral SERDs may not outperform AIs in the overall late-stage first-line population, the complete ER antagonism and degradation properties of oral SERDs could be more thorough than AIs in the adjuvant setting, particularly among high-risk patients. If the CAMBRIA trials are positive, Etcamah's market potential would far surpass the ESR1-mutant advanced population, serving as a core pillar for AstraZeneca's peak sales expectation of $5 billion for Etcamah.

However, data from the CAMBRIA trials is not expected until 2027 or later. In the interim, Etcamah's market uptake will depend on the gradual growth within the precise ESR1-mutant indication.